Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia

被引：47

作者：

Ghosn, Youssef ^{[1
]}

Kamareddine, Mohammed Hussein ^{[1
]}

Tawk, Antonios ^{[1
]}

Elia, Carlos ^{[2
]}

El Mahmoud, Ahmad ^{[1
]}

Terro, Khodor ^{[1
]}

El Harake, Nadia ^{[1
]}

El-Baba, Bachar ^{[1
]}

Makdessi, Joseph ^{[3
]}

Farhat, Said ^{[4
]}

机构：

[1] Univ Balamand, Fac Med & Med Sci, El Koura, Lebanon

[2] Univ Balamand, Fac Engn, Chem Engn, El Koura, Lebanon

[3] St George Hosp Univ Med Ctr, Dept Hematol Oncol, Beirut, Lebanon

[4] St George Hosp Univ Med Ctr, Dept Gastroenterol, Achrafieh Beirut, Lebanon

来源：

TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2019年 / 18卷

关键词：

myeloid; leukemia; inorganic; nanoparticles; drug resistance; CHRONIC MYELOID-LEUKEMIA; WALLED CARBON NANOTUBES; SILVER NANOPARTICLES; MULTIDRUG-RESISTANCE; CELL-LINE; BCR-ABL; GOLD NANOPARTICLES; CANCER-CELLS; BIOMEDICAL APPLICATIONS; IMATINIB MESYLATE;

D O I：

10.1177/1533033819853241

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic myeloid leukemia is a myeloproliferative disease where cells of myeloid linage display a t(9;22) chromosomal translocation leading to the formation of the BCR/ABL fusion gene and the continuous activation of tyrosine kinases. This malignancy has a peak incidence at 45 to 85 years, accounting for 15% of all leukemias in adults. Controlling the activity of tyrosine kinase became the main strategy in chronic myeloid leukemia treatment, with imatinib being placed at the forefront of current treatment protocols. New approaches in future anticancer therapy are emerging with nanomedicine being gradually implemented. Setting through a thorough survey of published literature, this review discusses the use of inorganic nanoparticles in chronic myeloid leukemia therapy. After an introduction on the basics of chronic myeloid leukemia, a description of the current treatment modalities of chronic myeloid leukemia and drug-resistance mechanisms is presented. This is followed by a general view on the applications of nanostrategies in medicine and then a detailed breakdown of inorganic nanocarriers and their uses in chronic myeloid leukemia treatment.

引用

页数：12

共 126 条

[41] THE CHRONIC MYELOCYTIC CELL-LINE K562 CONTAINS A BREAKPOINT IN BCR AND PRODUCES A CHIMERIC BCR/C-ABL TRANSCRIPT [J].